Jardiance (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

Boehringer Ingelheim

12 April 2022 - Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalisation for chronic heart failure.

Health Canada has granted marketing authorisation for Jardiance (empagliflozin) 10 mg for the treatment of chronic heart failure in adults as an adjunct to standard of care therapy, Boehringer Ingelheim and Eli Lilly have announced.

Read Boehringer Ingelheim press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada